SHR-1266

N/A

Report date: 2022/07/01 15:29:28
NME

Base Information

Drug NameSHR-1266
Drug Alias NameSHR-1266
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEternity Bioscience Inc
China Registration ClassN/A

Develop Information

Active CompaniesEternity Bioscience IncTg Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A